Latest Ratios: P/E Ratio -0.9x · EV/EBITDA N/A · ROE -55.4%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $67M | $66M | $78M | $149M | $397M | $1.0B | $2.8B | — | — |
| Enterprise Value | $30M | $29M | $38M | $124M | $302M | $881M | $2.4B | — | — |
| P/E Ratio → | -0.89 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.63 | 0.63 | 0.44 | 0.66 | 1.61 | 3.38 | 7.67 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.4% | -55.4% | -29.2% | -29.2% | -26.4% | -17.3% | -23.9% | — | — |
| ROA | -50.5% | -50.5% | -26.5% | -26.4% | -24.4% | -16.6% | -14.7% | -30.5% | -27.6% |
| ROIC | -63.4% | -63.4% | -38.0% | -34.1% | -38.6% | -60.3% | — | — | -46.0% |
| ROCE | -61.1% | -61.1% | -41.2% | -32.2% | -26.6% | -17.2% | -15.3% | -33.4% | -30.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.06 | 0.06 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.23 | -0.11 | -0.38 | -0.52 | -1.01 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($38M) exceeds total debt ($838000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.09 | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 | 56.90 | 22.57 | 26.75 |
| Quick Ratio | 10.09 | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 | 56.90 | 22.57 | 26.75 |
| Cash Ratio | 9.89 | 9.89 | 11.79 | 14.47 | 22.25 | 24.32 | 56.38 | 22.44 | 26.60 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $53M | $52M | $48M | $46M | $45M | $45M | $43M | $3M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PMVP stock.
PMV Pharmaceuticals, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
PMV Pharmaceuticals, Inc.'s return on equity (ROE) is -55.4%. The historical average is -30.2%.
Based on historical data, PMV Pharmaceuticals, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Imminent liquidity shortfall risk
Metrics are mathematically derived from official filings.
Capital Efficiency Deteriorating Amidst Burn
As reported in financial statements, PMVP's ROIC has trended downward from -7.1% in 2023Q4 to -24.4% in 2026Q1, reflecting the company's inability to generate productive returns while aggressively consuming capital to fund the ongoing Phase 2 PYRENE clinical trial for its lead candidate.
The consistent decline in ROIC suggests that the company is struggling to optimize its capital deployment as clinical costs mount without a corresponding increase in asset productivity. Investors should monitor this trend as it indicates that every dollar of invested capital is currently yielding a deeper negative return, which is unsustainable without a successful clinical readout.
Liquidity Position Nearing Critical Threshold
Based on recent SEC filings, PMVP's current ratio has compressed from 14.78 in 2023Q4 to 11.14 in 2026Q1, signaling that while the firm maintains a high nominal liquidity buffer, the rapid depletion of cash reserves warrants significant concern regarding its long-term operational runway.
Although the current ratio remains numerically high, it is misleading for a pre-revenue biotech where cash is the primary asset and liabilities are largely clinical accruals. The rapid erosion of this ratio suggests that the company is burning through its most liquid assets at an accelerating pace, leaving little room for error in its clinical development timeline.
Minimal Debt Usage Masks Risk
According to historical balance sheet data, PMVP maintains a negligible debt-to-equity ratio of 0.00 as of 2026Q1, which suggests that the company has avoided traditional debt financing in favor of equity-based capital raises to fund its high-risk clinical development pipeline.
While the lack of debt prevents immediate interest coverage concerns, it also implies that the company has exhausted its primary non-dilutive financing options. The reliance on equity markets for survival leaves existing shareholders highly exposed to the risk of significant dilution should the company need to raise capital to extend its runway.
Misapplication of Price-to-Book Valuation
As indicated by market data, the P/B ratio of 0.59 is frequently misapplied to PMVP, as it erroneously suggests the company is undervalued relative to its assets, failing to account for the fact that these assets are primarily cash being burned to fund clinical trials.
Investors should avoid using P/B as a valuation metric for this business model because it ignores the reality that the company's book value is essentially a countdown to insolvency. A more appropriate metric would be the cash-to-burn ratio, which provides a clearer picture of the company's survival horizon rather than its accounting net worth.